ANEB - Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target Analyst Says | Benzinga
H.C. Wainwright has initiated coverage on Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) with a Buy rating and a price target of $6.
Anebulo Pharmaceuticals is an emerging specialty biopharmaceutical company with a primary focus on developing therapy for acute cannabinoid intoxication (ACI), presenting a unique opportunity as approximately 2.1 million ACI cases are reported in U.S. emergency departments annually.
The company has produced compelling clinical proof-of-concept data, employing a visual analog scale (VAS) methodology to measure the substantial reduction in ACI symptoms, particularly the alteration in the sensation ...